In February 1994, the National Institute of Allergy and Infectious Diseases released preliminary findings of AIDS Clinical
Trials Group (ACTG) protocol 076 indicating that zidovudine therapy reduced the risk of perinatal human immunodeficiency virus type 1 (HIV-1) transmission by 67.507o [1] . The transmission rate was 25.507o among placebo recipients compared with 8.307o among zidovudine recipients. In that report, zidovudine therapy was initiated between 14 and 34 weeks of gestation, continued through pregnancy, and given intravenously during active labor, and oral zidovudine was given to the infant within 8-12 h of birth and continued for 6 weeks [2] .
Three limitations of the ACTG protocol 076 were noted [3] . First, the findings are directly applicable only to HIV-1-infected women who meet the study criteria: those with moderate or mild absolute CD4+ cell depletion (initial CD4"h count 32=200 cellsZ/xL) who had not yet received antenatal retroviral treatment during pregnancy. Because several studies have suggested that advanced immunosuppression is directly related to high rates of transmission [4, 5] , the effectiveness of zidovudine treatment among women with CD4"h cell counts of ^OOZ/zL will have important implications for the potential reduction of perinatal transmission. Second, the relative contributions of the antepartum, intrapartum, and infant treatment components of ACTG protocol 076 could not be determined; thus, it is not known how effective zidovudine would be if the protocol regimen were altered (e.g., antenatal component only or delivery component only) to increase compliance, minimize exposure and potential toxicity to mother and infant, and minimize cost. Third, information about the long-term side effects of zidovudine exposure in utero is not available.
The United States Public Health Service has developed guidelines for zidovudine prophylaxis to prevent perinatal transmission of HIV-1 with these limitations in mind, stipulating that the recommendations should be followed until further information becomes available [6] . While the ACTG protocol 076 findings are important, an urgent question remains: Would zidovudine therapy reduce perinatal transmission in other populations of HIV-1-infected women (e.g., those with low CD4"h cell counts or who seek medical care late in pregnancy)?
Although little is known about the potential benefits of zidovudine in women with more advanced stages of HIV disease or the efficacy of a given treatment component, two recent reports have suggested that the beneficial effects of zidovudine found in ACTG protocol 076 might extend to immunosuppressed women who receive only a portion of the zidovudine regimen. Zidovudine treatment reduced perinatal transmission by 250Zo among women whose CD4"H cell counts were generally lower than those of most subjects in ACTG protocol 076, and for them, zidovudine therapy was administered only during pregnancy or at delivery (or both) [7] . Preliminary data from our cohort also suggested that antenatal zidovudine alone might be effective, as significantly fewer of those who received zidovudine during pregnancy than of those who did not receive zidovudine during pregnancy transmitted the virus [8] .
We evaluated the effectiveness of antepartum zidovudine use alone in reducing mother-to-child transmission of HIV-1 among women with various levels of CD4+ cell depletion.
Patients and Methods
Subjects. Maternal demographic and intrapartum information, as well as data on zidovudine use, AIDS diagnoses, lymphocyte subsets during pregnancy, and hematologic data at delivery, were obtained from 432 HIV-1-seropositive women as part of their enrollment in a multicenter prospective study of perinatal HIV-1 transmission described elsewhere [4, 8] . Hematologic data, HIV-1 diagnostic testing, and physical examination findings were also obtained for infants as part of the study protocol. Gestational age at delivery was assessed by clinicians using the Ballard scale. Delivery complications causing potential excess fetal exposure to maternal blood, including prolonged membrane rupture (:M2 h), episiotomy, or internal fetal scalp monitoring, were also examined.
Pregnancies resulting in single births between March 1986 and December 1993 were included in this analysis if infant HIV-1 infection status had been determined and if maternal lymphocyte counts were obtained before delivery or by 2 weeks postpartum. If a mother was enrolled during more than one pregnancy, we included only the first study pregnancy, unless zidovudine was prescribed {n = 1) or T lymphocyte measurements were available (n = 15) during a subsequent pregnancy. In these 16 cases, only the subsequent pregnancy was included. Bias associated with this selection technique was assumed to be minimal since infection risk in second-bom HIV-1-exposed infants was not increased, regardless of whether the firstborn was infected or uninfected [9] .
Subjects received routine medical care from physicians at study hospitals, and some were prescribed zidovudine for their own indications at the discretion of the treating physician. Six who received zidovudine through participation in ACTG protocol 076 were excluded from this analysis. No attempt was made to assess compliance with the prescribed regimen, and subjects were considered to have remained on zidovudine for the duration of the pregnancy once treatment was begun. We also did not attempt to standardize the medical practices of clinicians caring for study subjects; the indications for and timing and dosage of zidovudine were the decision of the treating clinician. Side effects were not recorded as part of this study, and no study subject received other antiretroviral treatment.
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Results
Of 432 HIV-1-seropositive mothers whose expected delivery date was 6 months before the analysis, 111 did not meet the inclusion criteria for the logistic regression analysis. Of these, 92 did not have a T lymphocyte measurement available, 6 received zidovudine as part of ACTG protocol 076, and 12 who took zidovudine during pregnancy could not be evaluated because of miscarriage (1), early infant death (2), loss to follow-up before (4) or after (2) delivery, or insufficient data on child's infection status at time of analysis (3). One mother who received zidovudine during her second pregnancy and delivered uninfected twins was excluded from analysis because of the multiple delivery.
The 92 subjects excluded because of incomplete lymphocyte data were not significantly different from those included in the analysis with respect to the demographic characteristics in table 1 (data not shown), except that fewer had prenatal care (5107o vs. 8407o, P = .001) or an identified HIV-1 risk factor (7507o vs. 9107o, P < .001). While CD4+ lymphocyte data were not available to enable comparison of stage of disease with the sample analyzed, there were no differences in the proportion of AIDS-defining illnesses between the groups. Only 3 of the 92 reported zidovudine use during pregnancy, and the unadjusted transmission rates were nearly identical when the 92 were included in the analysis (1307o vs. 2207o; OR, 0.52; 9507o CI, 0.21-1.23).
For the 321 with complete data, the median time of lymphocyte measurement was 2 days postpartum (25th percentile, day of delivery; 75th percentile, 4 days postpartum). The median time from maternal lymphocyte determination to delivery (1 vs. 2 days, P ^ .15) and the mean chronologic age of the newborn at CBC specimen collection (3.76 vs. 4.8 days, P = .15) did not differ statistically between zidovudine and nonzidovudine groups. The median time from reported initiation of zidovudine therapy during pregnancy to delivery was 19 weeks (range, 4-42), and the median reported duration of zidovudine use during pregnancy did not differ significantly between the three levels of CD4+ cell count ^200, 28.3 weeks; 200-499, 17.9 weeks; ^99, 23.2 weeks, P = .18). Thirteen subjects with CD4+ cell counts of >499/pL reported using zidovudine during pregnancy (2 had been prescribed zidovudine before study enrollment, 5 had previous CD4+ cell counts of ^499, and 6 had counts of 500-650 during study enrollment and were prescribed zidovudine at the discretion of their physician).
HIV-1 risk factors, race, number of cesarean sections and premature deliveries, and duration of membrane rupture of those in the zidovudine treatment and nontreatment groups were similar (table 1). All of the mothers receiving zidovudine had received prenatal care compared with only 8207o of those who did not receive zidovudine (P = .002), but this was not an independent predictor of transmission (OR, 1.5; 9507o CI, 0.69-3.4). Subjects receiving zidovudine had significantly lower absolute CD4+ cell counts, CD4+ cell percentages, and CD4:CD8 ratios and higher CDS* cell percentages (table 2) and were more likely to have had an AIDS-defining illness diagnosed by 2 weeks postpartum (3207o vs. 1007o, P < .001).
The crude transmission rates were 1407o (6Z44) for subjects taking zidovudine during pregnancy and 2307o (621211) for those not taking zidovudine (OR, 0.55; 9507o CI, 0.22-1.4). The magnitude of the effect of zidovudine on decreasing transmission was similar in the groups with the lower absolute CD4H~ lymphocyte levels (OR, 0.42 for count ^00; OR, 0.46 for count 200-499; OR, 0.20 for count ^99). When CD4+ lymphocyte level was controlled for, the AOR for transmission of HIV-1 for those taking zidovudine during pregnancy compared with those not taking zidovudine was 0.36 (95(M) CI, 0.14-0.92). While zidovudine use was highly correlated with absolute CD4* cell count, no significant interaction term between CD4+ cell count and zidovudine use was detected, indicating that the efficacy of zidovudine was not related to CD4+ lymphocyte level. The overall perinatal transmission rate for the analysis cohort was 2l0Zo (68Z321). The crude transmission rate increased with CD4~H lymphocyte depletion, from 15^0 (27Z184) among subjects with CD4+ cell counts of ^99ZzzL to 28% (28Z100) among those with counts of 200-499ZziL and 35% (13Z37) among those with counts of ^OOZ/xL (table 3). Analysis by logistic regression adjusting for zidovudine use indicated that subjects with severe and moderate CD4+ lymphocyte depression were significantly more likely to transmit HIV-1 than were subjects with normal CD4+ lymphocyte levels (AOR, 4.1; 95^0 CI, 1.8-9.5; and AOR, 2.5; 95% CI, 1.3-4.6, respectively).
The proportion of birth defects and hematologic disorders, including anemia and hyperbilirubinemia, was similar in the newborn infants of both groups of mothers. Infants whose mothers received antenatal zidovudine were significantly more likely to have elevated mean corpuscular volume (MCV), defined as M12 fL [14] , within the first 2 weeks of life than were infants whose mothers did not receive zidovudine (38% [13Z34] vs. 5% [10Z195], P < .001), even when infant infection status and gestational age at delivery were controlled for. Likewise, more mothers who were prescribed zidovudine had elevated MCV (M00 fL) [15] than mothers who were not prescribed zidovudine ^/o [8Z31] vs. 3% [7Z211], P < .001). When maternal and infant MCV data were combined, 44% (17Z39) of the zidovudine group had elevated MCV in at least 1 member of the mother-infant pair compared with 6% (15Z 239) in the group not exposed to zidovudine (P < .001).
Comparison of intrapartum and maternal lymphocyte values between transmitting and nontransmitting subjects who were prescribed zidovudine is shown in table 4. While limited sample size makes interpretation difficult, among mothers reporting antenatal zidovudine use, transmitters tended to have more signs of HIV-1-related illness (more AIDS diagnoses, depressed CD4* lymphocyte counts and CD4+ cell percentages, and lower CD4:CD8 ratios) than nontransmitting mothers. However, among subjects receiving zidovudine during pregnancy, no differences in delivery complications, delivery mode, or duration of membrane rupture were seen when transmitting and nontransmitting subjects were compared.
Discussion
These results provide supportive evidence that oral zidovudine given during pregnancy before the onset of labor reduces the rate of perinatal HIV-1 transmission. These findings also provide evidence that this effect extends to women with severe CD4+ cell depletion, who are at highest risk of transmission [4, 5] but were excluded from the ACTG protocol 076. The treatment group in this analysis is restricted to women who received only oral zidovudine during the antenatal period; they did not receive intravenous zidovudine during labor, and their infants were not given zidovudine during the neonatal period.
ACTG protocol 076 found a highly significant (67^0) reduction in perinatal HIV-1 transmission associated with zidovudine given to the mother orally during pregnancy and intravenously during labor and to the infant orally for 6 weeks [2] . All motherinfant pairs in protocol 076 received all three regimens. A more recent report based on observational data also reported a significant but less pronounced reduction (25%) in transmission associated with zidovudine therapy delivered during pregnancy or labor (or both) [7] .
Because our study was observational and not randomized, it was limited in its ability to assess drug efficacy. Since compliance was not monitored, we cannot be certain how completely subjects adhered to their zidovudine regimens. The significantly higher erythrocyte MCV among subjects prescribed zidovudine and their newborn infants strongly suggests that in the final months of pregnancy, some of the mothers (^44^0) in the treatment group were taking zidovudine [16] .
Zidovudine at all clinically relevant dosage levels is known to produce macrocytosis within the second week of therapy [17, 18] , and similar effects on erythrocyte MCV in neonates have been reported [19] . The duration of this effect after zidovudine discontinuation is not known; however, zidovudineinduced macrocytosis is not likely to persist beyond the 80-day lifespan of the neonatal erythrocyte. Also, because neonatal MCV is high at birth and declines rapidly in the first days of life [14] , sampling ages for the CBC would affect the observed MCV in neonates. The age at sampling of neonatal CBCs was similar among the group whose mothers did and did not report zidovudine use. Thus, the macrocytosis noted in the zidovu- dine-exposed neonates was not an artifact of the timing of specimen collection. The presence of macrocytosis in mothers and newborns in this study can be considered a surrogate indicator of at least some zidovudine treatment in the last trimester of pregnancy. However, despite the presence of macrocytosis at birth, it is likely that some mothers did not fully comply with the zidovudine regimen. If not, the inclusion of any possible "treatment lapse" periods among mothers would diminish the observed magnitude of any zidovudine effect on the likelihood of mother-to-child HIV-1 transmission. Considering these factors, the similarity of our findings to those reported by ACTG protocol 076 is noteworthy (our AOR, 0.36, vs. ACTG OR, 0.26).
The results of this study do not address the relative contribution of intrapartum parenteral or neonatal zidovudine administration to reducing perinatal HIV-1 transmission. It is also not possible to determine if the treatment effect is different at different stages of disease (e.g., the antepartum component may be more important for women with advanced disease and higher virus load, while the intrapartum treatment may be more important for women with higher CD4* cell counts and lower virus load). However, the relative similarity of the reduction in transmission rate reported here and in ACTG protocol 076 suggests that a substantial portion of zidovudine's protective effect may occur when it is used during the antenatal period. Well-controlled trials assessing the timing and duration of therapy in HIV-1-infected pregnant women are needed to determine the minimally effective antiretroviral dose. In addition, pharmacokinetic studies of the bioavailability of oral dosing during labor and delivery will be important to establish the most effective, least toxic, and most widely applicable regimen.
Outcomes from clinical trials being planned in developing nations, where the protocol 076 treatment regimen cannot be given because of economic and logistic barriers, may provide additional information.
In combination with the findings from ACTG protocol 076, our results support the recent US Public Health Service guidelines [6] that recommend that zidovudine use be discussed and offered to all HIV-1-seropositive pregnant women. Our findings also indicate that while further research is needed, the maximal effect of zidovudine may occur in the antenatal portion of the ACTG protocol 076 treatment regimen, perhaps obviating the need for parenteral intrapartum and neonatal zidovudine.
